CELZ Overview

Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company dedicated to the advancement of identifying and translating novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology and orthopedics. The Company conducts substantially all of its commercial operations through its subsidiary, Creative Medical Technologies, Inc. Its products include AlloStem (CELZ-201-DDT) - allogenic human perinatal tissue derived cell program (clinical phase), ImmCelz (CELZ-100) - personalized supercharged immune therapy platform (pre-clinical trials), Type I Diabetes (CELZ-201 CREATE-1) - type I diabetes, Allostemspine Chronic Lower Back Pain (CELZ 201 ADAPT), Alova, CaverStem - erectile dysfunction treatment, FemCelz - female sexual function treatment, StemSpine - regenerative stem cell procedure for the treatment of degenerative disc disease (clinical trials), and OvaStem - stem cell therapy for premature ovarian failure.

Wall Street analysts forecast CELZ stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for CELZ is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Creative Medical Technology Holdings Inc revenue for the last quarter amounts to 0.00 USD, decreased

Creative Medical Technology Holdings Inc. EPS for the last quarter amounts to -0.48 USD, decreased -36.00

Creative Medical Technology Holdings Inc (CELZ) has 4 emplpoyees as of March 02 2026.

Today CELZ has the market capitalization of 6.33M USD.